DOCSLIB.ORG

The NIAID-Funded HIV Vaccine Trials Network (HVTN) Responds To

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
The NIAID-Funded HIV Vaccine Trials Network (HVTN) Responds To VOLUME 20, ISSUE 1: JUNE 2020 INSIDE THIS ISSUE The NIAID-funded HIV Vaccine Trials Network (HVTN) Responds to COVID-19 1 HIV VACCINE TRIALS NETWORK | COMMUNITY COMPASS | VOLUME 20, ISSUE 1: JUNE 2020 LETTERcities have some sort of “Stay at Please help us ensure that this Home” order* in place. On social publication is representative of our media, I see posts daily from people entire global HVTN community! who express concerns about (or HVTN members (who have access barriers to) getting tested; concerns to the HVTN member’s website) about themselves, friends, or family can use our submission page members who have possible or that offers the ability to submit actual symptoms of the virus; and content and articles for inclusion have seen just as many posts about in future issues. More information people who have died as a result of about this follows on the “Meet the complications of COVID-19. As I Community Compass Team” page. have sat and pondered about what to pen for this letter, I have thought Thank you for your continued Stephaun E. Wallace, Editor-in-Chief many times about the relationship support of the HVTN wherever you [email protected] between this disease and others, are in the world, for the work that Welcome to the latest edition of the including HIV, specifically for you do in whatever role you have HIV Vaccine Trials Network (HVTN) people and communities who are in the HVTN community, and for Community Compass. more vulnerable to negative health the impact we have been able to outcomes due to oppressive systems make in our collective history and In this issue, we highlight some and structures. Similar to HIV and communities, together. Though we of the recent World AIDS Day many other diseases, COVID-19 have come very far in response to activities, updates from some of our illustrates the very real impacts the HIV epidemic, we have so much sites and about some of our studies, of bias in healthcare/medical further to go to achieve an effective dive deeper into upcoming phase systems, poverty, historical trauma, global HIV vaccine. The HVTN 1 broadly neutralizing studies, as and other conditions impacting Community Compass team wants well as a very personal interview many communities, including to be everywhere you are, so please with our very own Dr. Larry Corey. communities of color. share with us what’s happening at The novel coronavirus SARS-CoV-2 your research sites, institutions, and which can result in COVID-19 I believe we will see this pandemic in your communities, so that we can disease has also cut short the life end, but we cannot achieve this end share it with the world. of one of our beloved colleagues, ethically by leaving anyone behind, Professor Gita Ramjee, who, in or without ensuring that appropriate Be well, addition to having been a renowned efforts are focused on those who are Stephaun E. Wallace scientist and role model to many, most vulnerable. There are many Stephaun E. Wallace, Ph.D. also served as Chief Specialist stakeholder mobilization efforts Editor-in-Chief, HVTN Community Compass Scientist and Director of the HIV happening in local and national Prevention Research Unit of the settings around the world with goals South African Medical Research of raising awareness about these Note: This was true at the time Council in Durban, South Africa. issues, and ensuring resources and of writing in April 2020. Please solutions are inclusive of those follow your institutional guidance The COVID-19 pandemic has taken most impacted and vulnerable. regarding any updates on center stage, becoming the topic We are a global community; let COVID-19 in your location. of conversation in nearly every us work together in response virtual space that I access. Many to this pandemic. HIV VACCINE TRIALS NETWORK | COMMUNITY COMPASS | VOLUME 20, ISSUE 1: JUNE 2020 2 CONTENTS Meet The Community Compass Team 4 Hope and a “Queen” 5 In Harmony - Transgender People and Early Phase HIV Vaccine Trials 8 Upcoming Events/Conferences/Meetings 10 Responding to a Four-Decade Old Epidemic While Thwarting the “New Kid on the Block” 11 Facing Down Pandemics: Dr. Larry Corey on HIV and COVID-19 15 The HVTN and HPTN Remember Gita Ramjee 17 Phase 1 Broadly Neutralizing Antibody Efforts 18 New SBS-CEU Staff at HVTN Core 22 Getting the Right Test for HIV 23 World AIDS Day Commemoration Event Report December 2019 Hosted By Synexus 25 Setshaba Research Centre World AIDS Day Commemoration 2019 28 Updates at Vanderbilt CRS 30 Mosaico: A Fleeting 72 Hours Inscribed to Memory 31 Public statement by the HIV Vaccine Trials Network (HVTN) on COVID-19 35 3 HIV VACCINE TRIALS NETWORK | COMMUNITY COMPASS | VOLUME 20, ISSUE 1: JUNE 2020 Our vision is an informed HVTN community that is aware of current events and activities relating to the HVTN network and its sites, advances in the field of HIV prevention and vaccination, as well as community priorities. We work to accomplish this by providing relevant information and updates to promote awareness, understanding, and support for HIV prevention and HIV vaccines, reaching global communities invested in the response to the HIV epidemic. We welcome submissions of articles on any topic for publication that is relevant to the HVTN community. Submissions must be exclusive to us, and not appear in any other publication. Submissions must be 500 words or less to comply with our layout and design requirements.Due to space limitations, we may need to hold publishing your article for a future issue. To submit articles for Community Compass, please go to the HVTN Members Site homepage, click on “About”, then click “Community Compass”, then click on “Submit to Community Compass”. Stephaun E. Wallace, Ph.D. Cody Shipman, Nina Feldman, Editor-in-Chief Layout & Design Production & Distribution Aziel Gangerdine, Gail Broder, MHS Contributor Contributing Editor HIV VACCINE TRIALS NETWORK | COMMUNITY COMPASS | VOLUME 20, ISSUE 1: JUNE 2020 4 Featured Article Hope and a “Queen” By: Aziel Gangerdine, HVTN Core, Seattle, WA, USA Communities, scientists, The Story of Science prevention, and HIV counseling investigators in the field of HIV and testing is mired with prevention, and other stakeholders A preventive vaccine that is safe challenges. Among others, HIV is are likely anticipating the and globally effective against HIV is a retrovirus with a high mutation announcement of the preliminary to HIV prevention research what a rate, and it targets the same T-cells results of two large-scale HIV queen represents on a chessboard. the immune system needs to prevention studies later this year. On the chessboard the queen is activate the immune system to Notably branded as AMP, antibody a game changer as it moves any fight infection. Additionally, a safe mediated prevention, both studies number of squares vertically, and effective HIV vaccine must are designed to determine whether horizontally and diagonally. prevent the transmission of the a broadly neutralizing antibody Similarly, a vaccine against HIV varying subtypes of HIV that are called VRC01 can prevent the will change the game by offering a found throughout the world. transmission of HIV in people. new long-lasting HIV prevention option, which may mitigate the The proof-of-concept AMP studies Fittingly, the NIAID-funded HIV need for daily medication like are not HIV vaccine studies. In HIV Vaccine Trials Network (HVTN), PrEP or post-exposure prophylaxis vaccine trials, study participants together with its our partners at (PEP) for some people; could get an HIV vaccine regimen and the HIV Prevention Trials Network offer herd immunity that protects researchers evaluate if vaccine- (HPTN) and the study funder and individual who get vaccinated induced antibodies and cellular sponsor the National Institute of and their communities; and immune responses are elicited Allergy and Infectious Diseases could potentially prevent the that may prevent HIV infection. (NIAID) of the National Institutes of asymptomatic transmission of The AMP studies skip that step Health (NIH), will lead discussions HIV from an infected person who by administering an antibody when the preliminary results of is not aware that they are infected through IV infusion directly the Antibody Mediated Prevention to others. In developing countries into the bloodstream of study (AMP) studies are shared. an HIV vaccine has the potential participants, looking to see if to alleviate pressure on poor having the antibodies will be Two interdependent stories will be social and health infrastructure protective. If efficacy is found, at the heart of the announcement: that is already under tremendous they will also help to establish the the stories of science and the will pressure from other diseases such amount of antibodies one needs and hope of communities. These as Tuberculosis (TB), diabetes in order to achieve protection. stories will be told through the and cancer. The socioeconomic By determining the amount of voices of the 4,625 AMP study benefits to any one society will antibodies needed to prevent HIV, participants, consisting of women be tremendous if an HIV vaccine this will help vaccine researchers in sub-Saharan Africa between is introduced to scale and made set a target for the amount of the ages of 18 – 40 years, and men accessible to communities. History antibodies that a future HIV and transgender people between reminds us that smallpox was vaccine may need to elicit. Having the ages of 18 – 50 years in the eradicated by a vaccine. In the this kind of target could help make Americas and Switzerland who United States, a long list of diseases future development of a vaccine have sex with men. These stories such as diphtheria, measles, more efficient and cost effective. will color a canvas set against mumps, rubella, and tetanus near a backdrop of the world’s HIV eradication as a result of vaccines.
Load more

Recommended publications
  • Country-Specific Factors That Compel South African Scientists to Engage
    COMMUNICATING SCIENCE ACROSS CULTURES, COMMENTARIES FROM SESSIONS AT PCST2018 Country-specific factors that compel South African scientists to engage with public audiences Marina Joubert Abstract A study in South Africa shed light on a set of factors, specific to this country, that compel South African scientists towards public engagement. It highlights the importance of history, politics, culture and socio-economic conditions in influencing scientists’ willingness to engage with lay audiences. These factors have largely been overlooked in studies of scientists’ public communication behaviours. Keywords Public engagement with science and technology; Science communication in the developing world DOI https://doi.org/10.22323/2.17040304 Introduction Science communication scholars increasingly recognise the importance of understanding the factors that motivate or constrain scientists in terms of their participation in science engagement [e.g. Davies, 2008; Rödder, 2012; Searle, 2013; Peters, 2014; Dudo and Besley, 2016]. Factors such as field of research, career stage, age and gender have been explored comprehensively [e.g. The Royal Society, 2006; Dunwoody, Brossard and Dudo, 2009; Bauer and Jensen, 2011; Bentley and Kyvik, 2011; Crettaz von Roten, 2011; Ecklund, James and Lincoln, 2012; Dudo, 2013; Peters, 2013; Johnson, Ecklund and Lincoln, 2014; TNS-BMRB, 2015; Chikoore et al., 2016]. Studies have focused on scientists’ interactions with journalists [e.g. Peters, 2013] and the impact of new media [e.g. Peters et al., 2014], or documented how scientists’ interactions with the public are influenced by the institutions where they work [e.g. Jacobson, Butterill and Goering, 2004; Grand et al., 2015; Marcinkowski et al., 2014] or their attitudes towards communication and the public [e.g.
    [Show full text]
  • HIV Risk Associated with Serum Medroxyprogesterone Acetate (MPA) Levels Among Women in East and Southern Africa: a Case- Control Study
    HHS Public Access Author manuscript Author ManuscriptAuthor Manuscript Author AIDS. Author Manuscript Author manuscript; Manuscript Author available in PMC 2020 March 15. Published in final edited form as: AIDS. 2019 March 15; 33(4): 735–744. doi:10.1097/QAD.0000000000002123. HIV risk associated with serum medroxyprogesterone acetate (MPA) levels among women in East and southern Africa: a case- control study Renee Heffron, University of Washington Randy Stalter, University of Washington Maria Pyra, University of Washington Corresponding author: Renee Heffron, 325 Ninth Avenue Box 359927, Seattle, WA 98104, [email protected], P: 206-520-3800, F: 206-530-3831. Author contributions RH and JMB conceived the study. RH wrote the first draft of the manuscript. RH, RS, and MP performed statistical analyses. JMB and JRL were awarded grant to fund the study. DWE and SWB oversaw laboratory technicians that performed analyses of progestin quantification. NM led site teams that collected the data. All authors contributed critical revisions to the analysis and interpretation and reviewed the final manuscript draft. Conflicts of Interest JMB is on an Advisory Committee of Gilead Sciences. All other authors declare no conflicts of interest. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention. Partners in Prevention HSV/HIV Transmission Study Team University of Washington Coordinating Center and Central Laboratories, Seattle, USA: Connie Celum (principal investigator), Anna Wald (protocol co-chair), Jairam Lingappa (medical director), Jared M. Baeten, Mary Campbell, Lawrence Corey, Robert W. Coombs, James P. Hughes, Amalia Magaret, M.
    [Show full text]
  • Samrcnewsletteraug2021.Pdf
    Building a healthy nation through research,NEWS innovation and transformation AUGUST 2021 WE ARE NOT SAFE UNTIL WE ARE ALL SAFE SOUTH AFRICAN MEDICAL RESEARCH COUNCIL OUR SCIENCE AT A GLANCE OUR SCIENCE AT A GLANCE Leading research and innovation in a Emerging Research and Practice on time of COVID-19 GBV in the time of COVID-19 While South Africa and the rest of the world continue to GHRU, led the development of the second GBV Strategy for confront the COVID-19 pandemic, there has been concern the Solidarity Fund (funded by the Bill and Melinda Gates of an upsurge in gender-based violence (GBV), particularly Foundation). Dr Shai provided expert advice to the Fund Since the start of COVID-19, the South African Medical foundation for enhanced infection control practices in during the lockdown. Reiterating our indelible mark in the to develop a Theory of Change and identify sustainable Research Council (SAMRC) has been responsive to healthcare settings, contributed to community surveillance country’s ongoing fight against GBV, we have led research solutions, while leading the stakeholder consultations to change, leading research and dialogue on the pandemic. initiatives and improved understanding of the pandemic in and dialogue in trying to understand what has happened prioritise the strategic focus areas and identified solutions. We also continued with pioneering cutting-edge medical South Africa. and make further strides to preventing women and girls innovations and programmes to support the South African from being exposed to GBV. This culminated into the allocation and provision of Government’s response to the pandemic to improve the R75 million in funding through a nation-wide Call for quality of life and health status of people in South Africa.
    [Show full text]
  • Faculty News Fourth Quarter 2014
    Faculty of Health Sciences, University of Cape Town Faculty News Fourth Quarter 2014 Undergraduate students celebrate at annual results bash p.3 highlights Final years rock graduation and Milestone anniversaries celebrated Prestigious awards to staff and 2014 3-5 excel once again 6-7 by IDM and Lung Institute 8-9 Ad-hominem promotions announced Preventing violence against High-level EU visit to HIV clinical Health and healthcare 20 years 11 trial sites launches EDCTP11 children – breaking the 15 16 after Mandela – Dean’s Forum funding intergenerational cycle Dean’s corner Dear colleagues A motion carried in Parliament, with a letter from the Speaker of Parliament, Baleka Mbete, to congratulate us on being the top faculty of health sciences in Africa – what a way to end our year! As always, our last quarter is our busiest as years of hard work bear fruit - evident from the announcements of academic achievements for both students and staff. This year has been no exception. I am absolutely delighted with recent announcements of several premier scholarly awards – from life-time achievements at the 2014 MRC Awards ceremony (Professors Robin Wood and Gregory Hussey); Fellows of UCT (Professors Gregory Hussey and Naomi Levitt) and recognition of teaching excellence (Prof Del Khan) to Rhodes scholarships at Oxford for three of our medical graduates (new graduates Dr Tinashe Chanauka and Dr Jessica Posel Price, and alumnus Dr Alex von Klemperer). This is the second year running, in my 18 months at UCT, that I have the honour of celebrating such prestigious levels of achievement within the Faculty.
    [Show full text]
  • SOUTH AFRICAN MEDICAL RESEARCH COUNCIL: MOVING FORWARDS MRC President, Professor Glenda Gray 18 August 2014 16H00 – 17H30
    SEMINAR INVITATION SOUTH AFRICAN MEDICAL RESEARCH COUNCIL: MOVING FORWARDS MRC President, Professor Glenda Gray 18 August 2014 16h00 – 17h30 Including FRC Young Investigators Best Publication 2013 Awards Refreshments to follow Wolfson Pavilion Lecture Theatre, UCT Medical Campus The Dean of the University of Cape Town’s Faculty of Health Sciences, Professor Wim de Villiers, invites you to attend a presentation from the new President of the South African MRC, Professor Glenda Gray, on the plans for the MRC moving forwards. Glenda Gray, MBBCH, FCPaeds (SA), DSc (honoris causa), an NRF A rated scientist, is the President of the South African Medical Research Council (MRC). Gray, who trained as a Medical Doctor and Paediatrician at the University of the Witwatersrand, co-founded and led the internationally renowned Perinatal HIV Research Unit, based at the Chris Hani Baragwanath Hospital in Soweto. She has expertise in mother to child transmission of HIV, HIV vaccines and microbicides. She is the Co-PI of the HIV Vaccine Trials Network and Director of the HVTN International Programs. In 2002, she was awarded the Nelson Mandela Health and Human Rights Award for pioneering work done in the field of Mother-to-Child Transmission of HIV-1. She is a member of the Academy of Science in South Africa, and chairs their standing committee on health. She is a member of the Institute of Medicine, of the National Academies, and serves on their Global Health Board. Gray has also been awarded the IAPAC “Hero of Medicine” award for work done in the field of HIV treatment in children and adults.
    [Show full text]
  • South Africa: Setting the Wrong Example
    © 1999 Nature America Inc. • http://medicine.nature.com EDITORIAL VOLUME 5 • NUMBER 1 • JANUARY 1999 South Africa: Setting the wrong example December 1st was “World AIDS Day” also offered to hold that price for five Health Minister and should resign—or and despite the welcome attention this years. Indeed, interest in this program was else there is another agenda. Senior scien- brought to the cause of AIDS patients such that in separate discussions with tists in the US have speculated that everywhere, it is disappointing to see provincial departments of health for two Zuma’s decision is politically motivated. how little interest the Western media has South African provinces (Gauteng and Zuma is said to be the main backer of an shown in the real issue of the day— Western Capetown) treatment under the effort by the South African government to South Africa’s recent decision not to program was begun in the hope that this abolish intellectual property rights on treat HIV-positive pregnant women with provincial experience would form the pharmaceuticals, with a view to pursuing the anti-viral drug AZT. This is a regret- basis of a national policy. the local production of patented drugs. table decision and South Africa should This arrangement had a lot to recom- In the year 2000, South Africa will host quickly reconsider. mend it and put South Africa on the the 13th World AIDS conference. The UNAIDS has estimated that in 1997, brink of an important and innovative meeting organizers and financial backers more than half a million infants acquired policy that would cut infant infection must be aware that world wide concern HIV from their mothers.
    [Show full text]
  • The Drive Behind the Legends of South African Science
    Book Review Page 1 of 1 The drive behind the legends of South African science BOOK TITLE: Legends of South African There is a long tradition of books which – through a compilation of biographies – seek to achieve a particular goal science of the author that is distinct from the purely narrative-historical. Thus Plutarch’s Lives of the Noble Greeks and Romans is a second-century series of biographies of famous men (and they were regrettably all men) designed to BOOK COVER: illustrate the moral virtues or failings which they had in common and to explore the influence of that elusive trait – character – on the lives of his subjects. In the 16th century, Vasari wrote his Lives of the Artists, intending thereby to map the course of the ‘rebirth’ of European civilisation that we call the Renaissance. The Academy of Science of South Africa (ASSAf) has now published a book comprising a set of biographical pieces on 53 eminent South African scholars and scientists who are all elected Academy Members but who in addition have been admitted to national orders by the Presidency, and/or have been awarded the country’s largest and most prestigious individual research grant, the Harry Oppenheimer Award, and/or have been awarded the Science-for-Society Gold Medal of the Academy itself. The text is the work of a team of experienced writers who have mostly used an interview-style format to enliven their stories. A few of the subjects are deceased, and in these EDITOR: instances close colleagues have provided the necessary material. As might be expected, the tone of all the pieces Academy of Science of is sympathetic rather than critical, with the special features of ‘defining moments’ and ‘little-known information’ South Africa (ASSAf) often providing engaging revelations in each narrative.
    [Show full text]
  • NRF Rating-Linked Awards
    A-RATED RESEARCHERS Prof J B [Jillian] Adler University of the Witwatersrand Prof L D [Lewis] Ashwal University of the Witwatersrand Prof K [Kelly] Chibale University of Cape Town Prof K [Keertan] Dheda University of Cape Town Prof G A [George] Ekama University of Cape Town Prof A [Andrew] Forbes University of the Witwatersrand Prof G E [Glenda] Gray SA Medical Research Council Prof L A [Lawrence] Hamilton University of the Witwatersrand Prof J D [Jan Dirk] Kramers University of Johannesburg Prof H P A [Hans-Peter] Kunzi University of Cape Town Prof B G [Barry] Lovegrove University of KwaZulu-Natal Prof R [Roy] Maartens University of the Western Cape Prof C W [Curtis] Marean Nelson Mandela University Prof J P [Josua] Meyer University of Pretoria Prof R P [Robert] Millar University of Pretoria Prof A J O [Anthony] Onwuegbuzie University of Johannesburg Prof A G R [Anthony] Reddie University of South Africa Prof L M [Linda] Richter University of the Witwatersrand Prof E P [Edward] Rybicki University of Cape Town Prof M J [Michael] Samways Stellenbosch University Prof H S [Simon] Schaaf Stellenbosch University Prof R A [Roger] Sheldon University of the Witwatersrand Prof B W [Beric] Skews University of the Witwatersrand Prof A M [Alan] Weinberg University of South Africa Prof Heather J Zar University of Cape Town P-RATED RESEARCHERS Dr S E [Sarah] Fawcett University of Cape Town Dr G P [Gareth] Hempson South African Environmental Observation Network Dr G H [Geoffrey] Howarth University of Cape Town Dr A M [Alistair] Price University of Cape
    [Show full text]
  • Mother-To-Child Transmission of HIV and South Africa's 'HIV Warrior'
    News and Views Page 1 of 1 Mother-to-child transmission of HIV and AUTHOR: South Africa’s ‘HIV warrior’ John Butler-Adam1 AFFILIATION: Professor Glenda Gray is the President and CEO of the South African Medical Research Council; Director of 1Academy of Science of International Programmes for HIV Vaccines Trial Network and the Programmes’ co-principal investigator; South Africa, Pretoria, Chairperson of the Board of the Global Alliance for Chronic Diseases; co-founder of the internationally recognised South Africa Perinatal HIV Research Unit in Soweto, South Africa; and the former Executive Director of the Perinatal HIV Research Unit, an affiliate of Wits University. Professor Gray is a member of the Institute of Medicine of the US CORRESPONDENCE TO: National Academies and also of the Academy of Science of South Africa and she chairs its Standing Committee on John Butler-Adam Health. Time magazine named her as one of the 100 most influential people in the world in 2017. HIV/AIDS – a spectrum of conditions caused by infection with the human immunodeficiency virus – is one of the EMAIL: major international infections experienced in the 20th and 21st centuries. Primarily spread by unprotected sex, the [email protected] virus can also be transmitted from an infected mother to her newly born baby, and it is in this area of extreme risk that Professor Gray, a trained paediatrician, has devoted much of her work – while also playing a critical role in KEYWORDS: fighting ignorance, evasion and AIDS denialism. Glenda Gray; AIDS denialism; AIDS activism While HIV infections were spreading across the world, the South African apartheid government’s response was largely characterised by evasion, and for most of the population, ignorance was the predominant state of affairs.
    [Show full text]
  • Prevention of Mother-To-Child Transmission of HIV (PMTCT) Through a Health Literacy Lens a Collection of Thoughtful Voices
    IMPACT & INNOVATION SERIES Prevention of Mother-to-Child Transmission of HIV (PMTCT) Through a Health Literacy Lens A Collection of Thoughtful Voices Featured Voices INTRODUCTION Kulsoom Ally, Corporate Social Investment Manager for Africa & the Middle East, Nokia Pacific Health Summit workshop, “Prevention of Moth- Franklin Apfel, Managing Director, World Health Communications er-to-Child Transmission of HIV (PMTCT) through a Associates Health Literacy Lens” focused on looking at health literacy challenges to PMTCT Jorge Bermudez, Executive Secretary, UNITAID Secretariat and ways to overcome these obstacles. The session examined the challenges from a Mitch Besser, Founder & Medical Director, mothers2mothers wide variety of perspectives from a diverse group of high-level stakeholders. Par- Brian Brink, Chief Medical Officer, Anglo American PLC ticipants hailed from science, industry, policy, academia, and medicine who do Ashraf Coovadia, Director, Empilweni Clinic Enhancing Childhood HIV Outcomes (ECHO); Head of Paediatric HIV Services, Rahima not often come together around this theme. Moosa Mother and Child Hospital Health literacy was defined as the ability to obtain, understand, and use health Glenda Gray, Executive Director, Perinatal HIV Research Unit, Chris Hani Baragwanath Hospital, University of the Witwatersrand information to improve health. The health literacy lens was applied to mothers, Alice Kang’ethe, Executive Vice President, Maternal & Child Health, practitioners, and policymakers. Participants addressed many questions,
    [Show full text]
  • HHS Public Access Author Manuscript
    HHS Public Access Author manuscript Author Manuscript Author ManuscriptAIDS. Author Author Manuscript manuscript; Author Manuscript available in PMC 2016 November 01. Published in final edited form as: AIDS. 2015 November ; 29(17): 2353–2359. doi:10.1097/QAD.0000000000000827. Effectiveness of Hormonal Contraception in HIV-Infected Women using Antiretroviral Therapy: A Prospective Study Maria Pyraa,b, Renee Heffrona,b, Nelly R. Mugob,d,e, Kavita Nandaf, Katherine K. Thomasa, Connie Celuma,b,c, Athena P. Kourtisg, Edwin Wereh, Helen Reesi, Elizabeth Bukusij, Jared M. Baetena,b,c, and for the Partners in Prevention HSV/HIV Transmission Study and Partners PrEP Study Teams* aDepartment of Epidemiology, University of Washington, Seattle, Washington, USA bDepartment of Global Health, University of Washington, Seattle, Washington, USA cDepartment of Medicine, University of Washington, Seattle, Washington, USA dDepartment of Obstetrics & Gynaecology, University of Nairobi, Nairobi, Kenya Corresponding author: Jared M. Baeten, University of Washington Department of Global Health, 325 Ninth Avenue Box 359927, Seattle, WA 98104, Phone: +1-206-520-3808, Fax: +1-206-520-3831, [email protected]. *Members of the study team listed after the Acknowledgements Data were presented at the 8th IAS Conference on HIV Pathogenesis, Treatment & Prevention in Vancouver, Canada. Authors' Contributions: JMB and RH conceived of the research question; MP conducted the data analysis. MP & JMB drafted the paper. NRM, KN, KKT, CC and APK assisted in refining the research question and analysis. EW, HR, and EB assisted in data collection. All authors contributed to editing the text and approved the final version. Partners in Prevention HSV/HIV Transmission Study Team: University of Washington Coordinating Center and Central Laboratories, Seattle, USA: Connie Celum (principal investigator), Anna Wald (protocol co-chair), Jairam Lingappa (medical director), Jared M.
    [Show full text]
  • Human Immunodeficiency Virus Antiretroviral Resistance and Transmission in Mother-Infant Pairs Enrolled in a Large Perinatal St
    Clinical Infectious Diseases MAJOR ARTICLE Human Immunodeficiency Virus Antiretroviral Resistance and Transmission in Mother-Infant Pairs Enrolled in a XX Large Perinatal Study Nava Yeganeh,1 Tara Kerin,1 Bonnie Ank,1 D. Heather Watts,2 Margaret Camarca,3 Esau C. Joao,4 Jose Henrique Pilotto,5,6 Valdilea G. Veloso,7 XXXX Yvonne Bryson,1 Glenda Gray,8 Gerhard Theron,9 Ruth Dickover,1 Mariza G. Morgado,10 Breno Santos,11 Regis Kreitchmann,12 Lynne Mofenson,13 and Karin Nielsen-Saines1 1Department of Pediatrics, David Geffen School of Medicine, University of California, Los Angeles; 2Office of the Global AIDS Coordinator and Health Diplomacy, US Department of State, Washington D.C.; 3Westat, Rockville, Maryland; 4Hospital Federal dos Servidores do Estado, 5Hospital Geral de Nova Iguaçu, 6Laboratório de AIDS e Imunologia Molecular, Instituto Oswaldo Cruz, Fundação Oswaldo Cruz (Fiocruz), and 7Laboratório de Pesquisa Clínica em Doenças Sexualmente Transmissíveis e AIDS, Instituto de Pesquisa Clínica Evandro Chagas, Fundação Oswaldo Cruz (Fiocruz), Rio de Janeiro, Brazil; 8Chris Hani Baragwanath Hospital, University of the Witwatersrand, Johannesburg, and 9Department of Obstetrics and Gynecology, Stellenbosch University, Cape Town, South Africa; 10Fundação Oswaldo Cruz (Fiocruz), Rio de Janeiro, and 11Hospital Conceicao, and 12Hospital Femina, Porto Alegre, Brazil; and 13Elizabeth Glaser Pediatric AIDS Foundation, Washington D.C. Background. The presence of antiretroviral drug-associated resistance mutations (DRMs) may be particularly problematic in human immunodeficiency virus (HIV)–infected pregnant women as it can lead to mother-to-child transmission (MTCT) of resistant HIV strains. This study evaluated the prevalence and the effect of antiretroviral DRMs in previously untreated mother-infant pairs.
    [Show full text]